financetom
MEG
financetom
/
Industrials
/
MEG
All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities
Montrose Environmental Group, Inc.MEG
USD
- At close
USD
- Until the end
The complete list of US stocks
1D
5D
1M
1Y
5Y
MAX
Overview >
% Change
Description >

Montrose Environmental Group, Inc. operates as an environmental services company in the United States and internationally.

The company operates in three segments: Assessment, Permitting and Response; Measurement and Analysis; and Remediation and Reuse.

The Assessment, Permitting and Response segment provides scientific advisory and consulting services to support environmental assessments, environmental emergency response and recovery, toxicology consulting and environmental audits and permits for current operations, facility upgrades, new projects, decommissioning projects, and development projects.

Its technical advisory and consulting services include regulatory compliance support and planning, environmental, and ecosystem and toxicological assessments and support during responses to environmental disruptions.

The Measurement and Analysis segment tests and analyzes air, water, and soil to determine concentrations of contaminants, as well as the toxicological impact of contaminants on flora, fauna, and human health.

Its services include source and ambient air testing and monitoring, leak detection, and advanced analytical laboratory services, such as air, storm water, wastewater, and drinking water analysis.

The Remediation and Reuse segment provides engineering, design, implementation, and operations and maintenance services primarily to treat contaminated water, remove contaminants from soil, or create biogas from waste.

The company serves technology, media, chemical, energy, power and utility, industrial and manufacturing, financial, and engineering industries, as well as local, state, provincial, and federal government entities.

Montrose Environmental Group, Inc. was founded in 2012 and is headquartered in North Little Rock, Arkansas.

Latest News >
Nip Group Insider Sold Shares Worth $442,030, According to a Recent SEC Filing
Nip Group Insider Sold Shares Worth $442,030, According to a Recent SEC Filing
Jul 2, 2026
06:16 AM EDT, 07/02/2026 (MT Newswires) -- Liwei Sun, Director, President, on June 30, 2026, sold 353,624 shares in Nip Group ( NIPG ) for $442,030. Following the Form 4 filing with the SEC, Sun has control over a total of 18,095,424 Class B1 ordinary shares of the company, with 18,095,424 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1966233/000149315226031618/xslF345X05/ownership.xml ...
Argentina power firm Genneia files for US IPO
Argentina power firm Genneia files for US IPO
Jul 2, 2026
July 2 (Reuters) - Argentine power producer Genneia filed for an initial public offering in the U.S. on Thursday. (Reporting by Arasu Kannagi Basil in Bengaluru; Editing by Joyjeet Das) ...
Market Chatter: Toyota to Partly Compensate Suppliers Hurt by Cancellation of Lexus EV
Market Chatter: Toyota to Partly Compensate Suppliers Hurt by Cancellation of Lexus EV
Jul 2, 2026
06:09 AM EDT, 07/02/2026 (MT Newswires) -- Toyota Motor ( TM ) will partially cover losses worth tens of billions of yen for suppliers affected by its decision to cancel the development of an electric vehicle, Nikkei Asia reported Wednesday. The cancellation of Lexus' LF-ZC sedan has hurt the company's supply chain, with some suppliers likely facing losses of up...
HUTCHMED's Orpathys Wins Conditional China Approval for Advanced Gastric Cancer
HUTCHMED's Orpathys Wins Conditional China Approval for Advanced Gastric Cancer
Jul 2, 2026
06:16 AM EDT, 07/02/2026 (MT Newswires) -- Hutchmed ( HCM ) said Thursday China's National Medical Products Administration granted conditional approval to marketing application of its therapy, Orpathys, to treat certain patients with locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma. The company said the approval is based on a phase 2 study in which Orpathys achieved its primary...
Copyright 2023-2026 - www.financetom.com All Rights Reserved